1. Introduction {#sec1-nutrients-09-00301}
===============

Urolithiasis is a common and recurring disease. The lifetime risk of renal stone disease is about 11% for men and 7% for women, and it tends to increase with changes in diet and climate globally \[[@B1-nutrients-09-00301]\]. In addition to high prevalence, it also has a recurrence rate as high as 50% at five years and 80%--90% at 10 years, respectively \[[@B2-nutrients-09-00301]\]. Although no data are available for China, medical care costs for urolithiasis were estimated to be \$3.79 billion spent in the United States in 2007, and it will increase to \$4.57 billion by 2030 due to the growth of the population and prevalence \[[@B3-nutrients-09-00301]\]. In addition to the economic burden, stones may result in hydronephrosis and life-threatening conditions, such as pyonephrosis and end-stage renal failure \[[@B4-nutrients-09-00301],[@B5-nutrients-09-00301]\]. Although many minimally-invasive treatment procedures, such as extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy, and ureteroscopy, have emerged for the treatment of renal and ureteral stones, all of these methods focus on the stone itself rather than "stone disease" \[[@B6-nutrients-09-00301],[@B7-nutrients-09-00301]\]. Therefore, further investigation and clarification of the pathogenesis of nephrolithiasis are high priorities for the development and improvement of medical therapy and prevention.

Calcium is the most frequent component of urinary calculi and is the major constituent of nearly 75% of stones \[[@B8-nutrients-09-00301]\]. Hypercalciuria is the most common abnormality identified in calcium stone formers (SFs) \[[@B8-nutrients-09-00301]\]. Common calcium stones may originate from Randall's plaques which can serve as anchors for stone growth \[[@B9-nutrients-09-00301]\]. Randall's plaques are composed of calcium and phosphorus \[[@B8-nutrients-09-00301],[@B9-nutrients-09-00301]\]. Vitamin D, a necessary hormone and nutrient for human, is the key regulator of calcium and phosphorus metabolism. Therefore, its major circulating metabolite, 25-hydroxyvitamin D~3~ (25(OH)D), and the active form, 1,25 dihydroxyvitamin D~3~ (1,25(OH)~2~D), are thought to play an important role in stone formation. Many studies have investigated the association between serum/plasma vitamin D and nephrolithiasis, however, their results are not consistent \[[@B10-nutrients-09-00301],[@B11-nutrients-09-00301]\]. Therefore, we performed this systematic review and meta-analysis to determine the difference of serum/plasma 1,25(OH)~2~D and 25(OH)D levels between SFs and non-stone formers (non-SFs). In addition, we compared the circulating vitamin D concentrations of hypercalciuria and normocalciuria SFs with that of controls.

2. Materials and Methods {#sec2-nutrients-09-00301}
========================

2.1. Literature Search and Study Selection {#sec2dot1-nutrients-09-00301}
------------------------------------------

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was followed by our study \[[@B12-nutrients-09-00301]\]. PubMed, Web of Science, The Cochrane Library, CNKI, and the Wanfang Database were systematically searched to identify relevant studies reporting the relationship between nephrolithiasis and circulating vitamin D. The search was performed on 31 December 2016. The initial search process was designed to find all relevant published original articles without limitation by year or language. Detailed search terms were: (stone\* OR calculi OR calculus OR urolithiasis OR nephrolithiasis) AND (Calcitriol OR Cholecalciferol OR "vitamin D\*" OR "1,25-Dihydroxyvitamin D\*" OR "1,25-dihydroxycholecalciferol" OR "1,25-(OH)~2~D~3~" OR "1,25(OH)~2~D~3~" OR "25-Hydroxyvitamin D" OR 25-hydroxycholecalciferol OR 25-(OH)D~3~ OR 25(OH)D~3~). Two authors (Henglong Hu and Jiaqiao Zhang) independently screened all of the citations returned from the search strategy to identify potentially eligible studies. Studies comparing the circulating vitamin D between SFs and healthy controls or between different type of SFs were screened further. Conference abstracts were not included, as they were deemed methodologically inappropriate. Disagreements were resolved through discussions. If disagreement persists, a third investigator (Shaogang Wang) will be consulted to attain consensus.

2.2. Data Extraction and Study Quality Assessment {#sec2dot2-nutrients-09-00301}
-------------------------------------------------

The following information from each eligible study will be extracted and entered into a pre-designed data extraction form by two investigators (Yunpeng Zhu and Yang Xun) independently: publication year and journal, authors, countries, study design, study period, sample size, participants' characteristics (age, gender), vitamin D types, measurement methods, means, and standard deviations of 1,25(OH)~2~D and/or 25(OH)D, and the units. Disagreements between the two authors will be resolved by rechecking the article and discussion. If disagreement persists, a third investigator (Shaogang Wang) will be consulted to attain consensus. The methodological quality of each study was evaluated by the two authors mentioned above using the Newcastle-Ottawa Scale for non-randomized controlled trials \[[@B13-nutrients-09-00301]\]. Possible publication bias was assessed using funnel plots of the outcome comparisons.

2.3. Data Processing and Statistical Analysis {#sec2dot3-nutrients-09-00301}
---------------------------------------------

To reduce heterogeneity and make it easier to describe and understand, serum/plasma 1,25(OH)~2~D levels provided not in pg/mL were converted to that and serum/plasma 25(OH)D levels provided in other units of measurement were converted to ng/mL. If the standard error of the mean rather than standard deviation is provided, then the standard deviation would be calculated by multiplying the standard error of the mean by the square of sample size. Combined means or standard deviations were calculated following the method described in the Cochrane Handbook \[[@B14-nutrients-09-00301]\]. For studies presenting continuous data as means and range, standard deviations were calculated using the methodology proposed by Hozo et al. as previously described \[[@B15-nutrients-09-00301],[@B16-nutrients-09-00301],[@B17-nutrients-09-00301]\]. The meta-analysis was performed using Review Manager Software V.5.3 (RevMan V.5.3, The Cochrane Collaboration, Oxford, UK). The weighted mean difference (WMD) with 95% confidence intervals (CIs) were used as the summary statistics for continuous variables. Heterogeneity among studies was evaluated by chi-square test and *I*^2^ statistics. Moreover, the pooled estimates were calculated with the fixed-effect model if no significant heterogeneity was detected; otherwise, the random-effect model was used. The pooled effects were determined by the *z* test. A *p*-value less than 0.05 was considered statistically significant. Funnel plots assessing publication bias were generated using RevMan v.5.3. Additionally, a sensitivity analysis was performed by pooling only studies with a relatively high score (scored 8 and 9) of Newcastle-Ottawa Scale.

3. Results {#sec3-nutrients-09-00301}
==========

3.1. Literature Search and Study Selection {#sec3dot1-nutrients-09-00301}
------------------------------------------

The literature search and study selection process are depicted in [Figure 1](#nutrients-09-00301-f001){ref-type="fig"}a. Electronic searches revealed 1061 articles. After screening of titles and abstracts, we considered 55 that were relevant to our purpose and, therefore, we retrieved the full-text articles, but four studies had only abstracts available. After full-text analysis, another 19 studies were excluded for the following reasons: 14 had no control group and no useful data, three did not provide standard deviations, and two reported duplicate data. Finally, 32 studies fulfilled our eligibility criteria and were enrolled in the meta-analysis \[[@B10-nutrients-09-00301],[@B11-nutrients-09-00301],[@B18-nutrients-09-00301],[@B19-nutrients-09-00301],[@B20-nutrients-09-00301],[@B21-nutrients-09-00301],[@B22-nutrients-09-00301],[@B23-nutrients-09-00301],[@B24-nutrients-09-00301],[@B25-nutrients-09-00301],[@B26-nutrients-09-00301],[@B27-nutrients-09-00301],[@B28-nutrients-09-00301],[@B29-nutrients-09-00301],[@B30-nutrients-09-00301],[@B31-nutrients-09-00301],[@B32-nutrients-09-00301],[@B33-nutrients-09-00301],[@B34-nutrients-09-00301],[@B35-nutrients-09-00301],[@B36-nutrients-09-00301],[@B37-nutrients-09-00301],[@B38-nutrients-09-00301],[@B39-nutrients-09-00301],[@B40-nutrients-09-00301],[@B41-nutrients-09-00301],[@B42-nutrients-09-00301],[@B43-nutrients-09-00301],[@B44-nutrients-09-00301],[@B45-nutrients-09-00301],[@B46-nutrients-09-00301],[@B47-nutrients-09-00301]\].

3.2. Systematic Reviews of Included Studies {#sec3dot2-nutrients-09-00301}
-------------------------------------------

[Table 1](#nutrients-09-00301-t001){ref-type="table"} summarizes characteristics of the eligible studies published from 1977 to 2016. Seven of the studies were conducted in the USA, three in Canada, three in Italy, two in France, two in Iran, two in Spain, two in Sweden, two in Turkey, and one each in Australia, Belgium, Brazil, Germany, Japan, Korea, Netherlands, Pakistan, and Switzerland. All studies were observational and two were cohort studies \[[@B44-nutrients-09-00301],[@B46-nutrients-09-00301]\]. Most studies clearly demonstrated that they ruled out hyperparathyroidism and/or renal tubule acidosis \[[@B10-nutrients-09-00301],[@B11-nutrients-09-00301],[@B18-nutrients-09-00301],[@B19-nutrients-09-00301],[@B22-nutrients-09-00301],[@B26-nutrients-09-00301],[@B27-nutrients-09-00301],[@B29-nutrients-09-00301],[@B33-nutrients-09-00301],[@B34-nutrients-09-00301],[@B36-nutrients-09-00301],[@B43-nutrients-09-00301]\], some also excluded patients using calcium and/or vitamin D \[[@B18-nutrients-09-00301],[@B26-nutrients-09-00301],[@B29-nutrients-09-00301],[@B35-nutrients-09-00301],[@B39-nutrients-09-00301],[@B42-nutrients-09-00301]\]. Seventeen studies described their criteria of hypercalciuria and they were not consistent \[[@B18-nutrients-09-00301],[@B19-nutrients-09-00301],[@B20-nutrients-09-00301],[@B22-nutrients-09-00301],[@B24-nutrients-09-00301],[@B26-nutrients-09-00301],[@B28-nutrients-09-00301],[@B29-nutrients-09-00301],[@B32-nutrients-09-00301],[@B35-nutrients-09-00301],[@B36-nutrients-09-00301],[@B37-nutrients-09-00301],[@B38-nutrients-09-00301],[@B42-nutrients-09-00301],[@B43-nutrients-09-00301],[@B45-nutrients-09-00301]\], twelve of which defined hypercalciuria as urinary calcium excretion of more than 300 mg/24 h for men and 250 mg for women or 4 mg/kg/day \[[@B19-nutrients-09-00301],[@B23-nutrients-09-00301],[@B26-nutrients-09-00301],[@B28-nutrients-09-00301],[@B29-nutrients-09-00301],[@B32-nutrients-09-00301],[@B35-nutrients-09-00301],[@B36-nutrients-09-00301],[@B38-nutrients-09-00301],[@B42-nutrients-09-00301],[@B43-nutrients-09-00301]\]. The subjects were on a free or normal calcium diet in some studies \[[@B10-nutrients-09-00301],[@B11-nutrients-09-00301],[@B19-nutrients-09-00301],[@B21-nutrients-09-00301],[@B22-nutrients-09-00301],[@B26-nutrients-09-00301],[@B28-nutrients-09-00301],[@B29-nutrients-09-00301],[@B32-nutrients-09-00301],[@B35-nutrients-09-00301],[@B36-nutrients-09-00301],[@B39-nutrients-09-00301],[@B43-nutrients-09-00301]\], while restricted calcium diets were adopted in some others \[[@B24-nutrients-09-00301],[@B27-nutrients-09-00301],[@B31-nutrients-09-00301],[@B33-nutrients-09-00301],[@B34-nutrients-09-00301],[@B38-nutrients-09-00301]\]. Nineteen of the included trials only tested serum/plasma 1,25(OH)~2~D \[[@B19-nutrients-09-00301],[@B20-nutrients-09-00301],[@B22-nutrients-09-00301],[@B24-nutrients-09-00301],[@B26-nutrients-09-00301],[@B27-nutrients-09-00301],[@B28-nutrients-09-00301],[@B30-nutrients-09-00301],[@B31-nutrients-09-00301],[@B32-nutrients-09-00301],[@B33-nutrients-09-00301],[@B34-nutrients-09-00301],[@B35-nutrients-09-00301],[@B36-nutrients-09-00301],[@B37-nutrients-09-00301],[@B38-nutrients-09-00301],[@B39-nutrients-09-00301],[@B42-nutrients-09-00301],[@B43-nutrients-09-00301]\], six only assessed 25(OH)D \[[@B18-nutrients-09-00301],[@B25-nutrients-09-00301],[@B40-nutrients-09-00301],[@B41-nutrients-09-00301],[@B44-nutrients-09-00301],[@B47-nutrients-09-00301]\], and the others evaluated the two metabolites at the same time \[[@B10-nutrients-09-00301],[@B11-nutrients-09-00301],[@B21-nutrients-09-00301],[@B22-nutrients-09-00301],[@B29-nutrients-09-00301],[@B45-nutrients-09-00301],[@B46-nutrients-09-00301]\]. The most commonly used measurement method for 1,25(OH)~2~D and 25(OH)D was radioimmunoassay. Twenty studies were rated as being relatively high in quality according to the Newcastle-Ottawa Scale \[[@B18-nutrients-09-00301],[@B19-nutrients-09-00301],[@B21-nutrients-09-00301],[@B23-nutrients-09-00301],[@B24-nutrients-09-00301],[@B27-nutrients-09-00301],[@B28-nutrients-09-00301],[@B29-nutrients-09-00301],[@B30-nutrients-09-00301],[@B33-nutrients-09-00301],[@B35-nutrients-09-00301],[@B37-nutrients-09-00301],[@B38-nutrients-09-00301],[@B39-nutrients-09-00301],[@B40-nutrients-09-00301],[@B42-nutrients-09-00301],[@B43-nutrients-09-00301],[@B45-nutrients-09-00301],[@B46-nutrients-09-00301],[@B47-nutrients-09-00301]\]. The other 12 were scored as 6 or 7, mainly due to some important baseline characteristics of the groups, such as age, sex, and/or use of vitamin D were not well matched or clearly reported \[[@B10-nutrients-09-00301],[@B11-nutrients-09-00301],[@B20-nutrients-09-00301],[@B22-nutrients-09-00301],[@B25-nutrients-09-00301],[@B26-nutrients-09-00301],[@B31-nutrients-09-00301],[@B32-nutrients-09-00301],[@B34-nutrients-09-00301],[@B36-nutrients-09-00301],[@B41-nutrients-09-00301],[@B44-nutrients-09-00301]\]. Additionally, a sensitivity analysis was conducted in order to detect and rule out any potential bias associated with the effects of such studies on the results as a whole. We also analyzed the possible publication bias by generating funnel plots of all of the evaluated comparisons. As an example, [Figure 1](#nutrients-09-00301-f001){ref-type="fig"}b represents the funnel plot of the comparison of 1,25(OH)~2~D between stone and control group. As well as the other nine funnel plots presented in [Figure S1](#app1-nutrients-09-00301){ref-type="app"}, it does not show an obvious asymmetry; in other words, suggesting that publication bias was not significant ([Figure 1](#nutrients-09-00301-f001){ref-type="fig"}b).

3.3. Meta-Analysis Results {#sec3dot3-nutrients-09-00301}
--------------------------

Pooling the data from 23 studies that assessed serum/plasma 1,25(OH)~2~D status revealed SFs had a significantly higher level of 1,25(OH)~2~D (WMD, 10.19 pg/mL; 95% CI, 4.31--16.07; *p* = 0.0007; [Figure 2](#nutrients-09-00301-f002){ref-type="fig"}a) than controls. Further analysis demonstrated that, compared to non-SFs, calcium stone patients and hypercalciuria stone patients had increased concentrations of 1,25(OH)~2~D (WMD, 11.28 pg/mL; 95% CI, 4.07--18.50; *p* = 0.002 and WMD, 9.41 pg/mL; 95% CI, 0.15--18.67; *p* = 0.05, respectively). The circulating 1,25(OH)~2~D in hypercalciuria SFs tended to be higher than that of normocalciuria ones, while not reaching significance (WMD, 2.75 pg/mL; 95% CI, −0.20--5.69; *p* = 0.07). Normocalciuria SFs had elevated 1,25(OH)~2~D levels than the control subjects, but the difference was not significant (WMD, 6.85 pg/mL; 95% CI, −5.00--18.71; *p* = 0.26).

[Figure 3](#nutrients-09-00301-f003){ref-type="fig"} shows the meta-analysis results of studies evaluating 25(OH)D levels. Meta-analysis of these studies showed that stone patients, calcium stone patients and normocalciuria SFs had similar serum/plasma 25(OH)D concentration with controls (WMD, 0.88 ng/mL, 95% CI, −1.04--2.80, *p* = 0.37; WMD, −0.63 ng/mL, 95% CI, −2.72--1.47, *p* = 0.56; WMD, 0.94 ng/mL, 95% CI, −3.55--5.43, *p* = 0.68, respectively). However, compared with non-SFs and normocalciuria stone patients, hypercalciuria SFs had markedly higher level of circulating 25(OH)D (WMD, 5.02 ng/mL; 95% CI, 0.99--9.06; *p* = 0.01 and WMD, 5.02 ng/mL; 95% CI, 2.14--7.90; *p* = 0.0006, respectively).

3.4. Sensitivity Analysis {#sec3dot4-nutrients-09-00301}
-------------------------

Further sensitivity analysis was performed by removing studies scoring lower than 8 according to Newcastle-Ottawa Scale. As showed in [Table 2](#nutrients-09-00301-t002){ref-type="table"}, sensitivity analyses generated comparable results and suggested that the results of this meta-analysis were relatively stable and reliable. It is notable that the circulating 1,25(OH)~2~D of hypercalciuria SFs becomes significantly higher than that of the controls.

4. Discussion {#sec4-nutrients-09-00301}
=============

Urolithiasis, an old disease, continues to be a major cause of kidney function loss and creates a significant burden on our public health system. Although many medical or surgical treatment methods have been developed, a necessary step to improve preventive and treatment outcomes is better understanding of the etiology and pathogenesis. Many systemic diseases, such as primary hyperparathyroidism, bowel disease and renal tubular acidosis, can cause the formation of calcium stones, but the majority of SFs are found to be with no systemic illness and they are called idiopathic SFs \[[@B48-nutrients-09-00301]\]. This study was mainly focused on these patients.

Through a comprehensive meta-analysis, our results demonstrate that, compared to control subjects, urinary stone patients and calcium SFs have significantly higher 1,25(OH)~2~D concentrations while having similar 25(OH)D serum/plasma values. Although 25(OH)D is the major vitamin D circulating metabolite, 1,25(OH)~2~D is known to be the most important metabolite in regulating calcium and phosphorus metabolism and bone resorption. Calcium regulates a wide range of biological processes and the main constitution of bone. These findings suggest that 1,25(OH)~2~D might be an important intrinsic factor in stones, especially calcium stone formation.

Many idiopathic SFs have metabolic abnormalities that can be detected by 24 h urinalysis, but are not considered to be systemic diseases \[[@B48-nutrients-09-00301]\]. Hypercalciuria is the most common metabolic abnormality in patients with urolithiasis and the principal correlates of Randall's plaque coverage \[[@B8-nutrients-09-00301],[@B48-nutrients-09-00301],[@B49-nutrients-09-00301]\]. One prerequisite for calcium oxalate overgrowth on Randall's plaque is calcium oxalate supersaturation, which is also strongly linked to hypercalciuria. Subgroup meta-analyses were implemented to further clarify the potential relationship between hypercalciuria and vitamin D. Strikingly, the results demonstrated elevated circulating 1,25(OH)~2~D and 25(OH)D levels in hypercalciuria SFs than controls and normocalciuria SFs. This can be partly explained by the role of vitamin D in promoting intestinal absorption of calcium and bone reabsorption. Further analysis also found that 1,25(OH)~2~D levels were higher in normocalciuria stone patients than controls, but failed to reach significance (WMD, 6.85 pg/mL; 95% CI, −5.00--18.71, *p* = 0.26; *p* = 0.12 in the sensitivity analysis). The *p* value was relatively small and it further decreased in the sensitivity analysis, which suggests that the association between increased 1,25(OH)~2~D and normocalciuria stones may not be as tight as between higher 1,25(OH)~2~D concentrations and hypercalciuria stones. However, this still needs additional large volume studies to confirm. Similarly, normocalciuria SFs had comparable serum/plasma concentration of 25(OH)D with controls (WMD, 0.94 ng/mL, 95% CI, −3.55--5.43, *p* = 0.68; *p* = 0.94 in the sensitivity analysis).

Urolithiasis is a multifactorial disease and both genetic and environmental factors have effects on its onset and severity. Among these factors, the vitamin D signaling pathway plays an important role. Recent evidence has identified loss of function mutations in CYP24A1, encoding the vitamin D-24-hydroxylase which regulates the catabolism of 1,25(OH)~2~D, can result in high circulating levels of 1,25(OH)~2~D, hypercalcemia, hypercalciuria, and nephrolithiasis in humans \[[@B50-nutrients-09-00301]\]. Our, and other team's, studies using genetic hypercalciuric stone-forming rats showed that vitamin D could take part in the pathogenesis of urolithiasis \[[@B51-nutrients-09-00301],[@B52-nutrients-09-00301],[@B53-nutrients-09-00301]\]. Vitamin D receptor knockdown in genetic hypercalciuric rats reduced calcium phosphate deposits in the kidneys \[[@B52-nutrients-09-00301]\]. A recent meta-analysis displayed a significant contribution of vitamin D receptor polymorphisms to urolithiasis risk \[[@B54-nutrients-09-00301]\]. Vitamin D receptor gene polymorphisms may influence vitamin D function, as well as its serum levels. In addition to the above, supplementation of vitamin D in humans and rats can induce hypercalciuria, renal calcification, and/or renal stones \[[@B55-nutrients-09-00301],[@B56-nutrients-09-00301]\].

A recent meta-analysis evaluating the association between serum vitamin D levels and the risk of kidney stone was performed by Wang et al. \[[@B57-nutrients-09-00301]\]. Although the meta-analysis also showed that serum vitamin D levels in kidney stone patients were significantly higher than that in non-kidney stone controls, several limitations or mistakes existed, and these would make the results unconvincing. First, and the most importantly, two included studies only consisted of stone patients and some stone patients were mistakenly regarded as healthy controls. Second, the meta-analysis pooled 1,25(OH)~2~D and 25(OH)D indiscriminately. This seems inappropriate and would increase the bias. Third, this meta-analysis only included seven articles involving 451 kidney stone cases and 482 controls, which is much less than ours. Moreover, some values in the analysis were not accurate and, on some occasions, the standard error was taken as standard deviation.

The inclusion of large number of cases in this meta-analysis provided us with sufficient power to detect the association between increased circulating 1,25(OH)~2~D and urolithiasis. The results also provide some implications for the research of vitamin D supplementation. Although Reid and colleagues' study challenged the role of vitamin D supplementation in improving bone mineral density \[[@B58-nutrients-09-00301],[@B59-nutrients-09-00301]\], supplementation of vitamin D has many beneficial effects \[[@B60-nutrients-09-00301],[@B61-nutrients-09-00301],[@B62-nutrients-09-00301],[@B63-nutrients-09-00301]\]. However, many doctors and patients are concerned about whether vitamin D repletion will increase the risk of urolithiasis, especially in SFs \[[@B64-nutrients-09-00301]\]. A recent systematic review and meta-analysis demonstrated that long-term vitamin D supplementation resulted in increased risks of hypercalcemia and hypercalciuria, but did not increase risk of kidney stones \[[@B55-nutrients-09-00301]\]. A randomized controlled trial conducted in 21 SFs found that high-dose and low-dose vitamin D supplementation had no effect on urine calcium excretion or the supersaturation of calcium salts \[[@B65-nutrients-09-00301]\]. However, the results still need further confirmation by large randomized controlled trials.

However, several limitations also exist in our analysis. First, the number of recruited patients in some studies was relatively small. However, the complete analysis of 32 different studies and the stable results from sensitivity analysis strengthen our conclusion. Second, meta-analyses of cross-sectional studies cannot be used for establishing a causative link, but this study provides reliable evidence for the association between 1,25(OH)~2~D and nephrolithiasis. Third, the heterogeneity of the included studies is high and it may be due to the differences in ethnicity, participant ages, measurement methods, measurement seasons, vitamin D supplementations, and hypercalciuria definitions. We used the random model to minimize the effect. Finally, we are unable to use these results to suggest specific pathogenesis and treatment strategies due to limited information.

5. Conclusions {#sec5-nutrients-09-00301}
==============

The current evidence demonstrated that, compared to control subjects, patients with urinary stone, calcium stones had significantly higher levels of 1,25(OH)~2~D, while having similar concentration of 25(OH)D. The circulating concentrations of 1,25(OH)~2~D and 25(OH)D were higher in hypercalciuria stone patients than controls and normocalciuria stone patients. Normocalciuria stone patients and controls have comparable levels of 25(OH)D. These results suggest that increased circulating 1,25(OH)~2~D is associated with urinary stones and a higher level of circulating 25(OH)D is significantly associated with hypercalciuria urolithiasis. Further studies are still needed to reconfirm and clarify the role of vitamin D in the pathogenesis of stones, thus, bringing about new approaches for prevention and treatment of this disease.
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nutrients-09-00301-t001_Table 1

###### 

Characteristics of included studies.

  Surname of First Author                         Year   Country       NOS Score   Sample Type   Measurement Method for 1,25(OH)~2~D               Measurement Method For 25(OH)D                    Stone Component             Groups   Participant Number   Age (Mean ± SD)   Sex Ratio (M/F)
  ----------------------------------------------- ------ ------------- ----------- ------------- ------------------------------------------------- ------------------------------------------------- --------------------------- -------- -------------------- ----------------- -----------------
  Gray \[[@B10-nutrients-09-00301]\]              1977   USA           7/9         plasma        Chromatin binding assay                           competitive protein binding assay                 calcium oxalate/apatite     SG       26                   48                24/2
                                                                                                                                                                                                                                 CG       48                   25                27/21
  Caldas \[[@B11-nutrients-09-00301]\]            1978   USA           7/9         plasma        Cytosol binding assay                             competitive protein binding assay                 calcium oxalate/apatite     SG       23                   NA                20/3
                                                                                                                                                                                                                                 CG       36                   NA                22/14
  Berlin \[[@B18-nutrients-09-00301]\]            1982   Sweden        8/9         serum         \-                                                Isotope dilution-mass spectrometry                calcium oxalate/phosphate   HSG      38                   NA                16/6
                                                                                                                                                                                                                                 NSG      32                   NA                34/4
  D'Amour \[[@B19-nutrients-09-00301]\]           1984   Canada        7/9         serum         Competitive binding assay                         \-                                                NA                          HSG      21                   36.16 ± 31.39     17/4
                                                                                                                                                                                                                                 NSG      8                    31.8 ± 18.38      3/5
  De Leenheer \[[@B20-nutrients-09-00301]\]       1985   Belgium       7/9         serum         Radioimmunoassay                                  \-                                                NA                          SG       62                   NA                NA
                                                                                                                                                                                                                                 CG       91                   NA                NA
  Netelenbos \[[@B21-nutrients-09-00301]\]        1985   Netherlands   8/9         serum         Competitive protein binding assay                 Competitive protein binding assay                 NA                          SG       160                  43 ± 14           106/54
                                                                                                                                                                                                                                 CG       203                  39 ± 11           147/70
  Berlin \[[@B22-nutrients-09-00301]\]            1986   Sweden        8/9         serum         Radioreceptor assay                               Isotope dilution-mass spectrometry                NA                          SG       79                   43 ± 3.33         NA
                                                                                                                                                                                                                                 CG       8                    31 ± 6.83         NA
  Sutton \[[@B23-nutrients-09-00301]\]            1986   Canada        9/9         serum         Cytosol receptor assay                            \-                                                Calcium                     SG       10                   47 ± 11           10/0
                                                                                                                                                                                                                                 CG       10                   47 ± 10           10/0
  Bataille \[[@B24-nutrients-09-00301]\]          1987   France        8/9         plasma        Radioimmunoassay                                  \-                                                Calcium                     SG       51                   NA                29/22
                                                                                                                                                                                                                                 CG       12                   NA                7/5
  Niazi \[[@B25-nutrients-09-00301]\]             1987   Parkistan     7/9         serum         \-                                                NA                                                NA                          SG       10                   34                NA
                                                                                                                                                                                                                                 CG       7                    26                NA
  Nunziata \[[@B26-nutrients-09-00301]\]          1991   Italy         7/9         serum         Competitive binding assay                         \-                                                NA                          SG       101                  NA                NA
                                                                                                                                                                                                                                 CG       55                   NA                NA
  Wong \[[@B27-nutrients-09-00301]\]              1992   Australia     8/9         serum         Microassay                                        \-                                                Calcium                     SG       59                   46.59 ± 13.92     51/8
                                                                                                                                                                                                                                 CG       31                   43.52 ± 13.55     20/11
  Giannini \[[@B28-nutrients-09-00301]\]          1993   Italy         8/9         serum         Competitive protein binding assay                 \-                                                Calcium                     HSG      47                   40.5 ± 2.8        NA
                                                                                                                                                                                                                                 NSG      28                   48.8 ± 2.6        NA
  Hess \[[@B29-nutrients-09-00301]\]              1995   Switzerland   8/9         serum         Radioimmunoassay                                  Radioimmunoassay                                  Calcium                     SG       57                   NA                NA
                                                                                                                                                                                                                                 CG       15                   NA                NA
  Jarrar \[[@B30-nutrients-09-00301]\]            1996   Germany       9/9         serum         Radioreceptor assay                               \-                                                Calcium                     SG       111                  54.92 ± 23.36     64/47
                                                                                                                                                                                                                                 CG       44                   53.34 ± 18.66     22/22
  Scott \[[@B31-nutrients-09-00301]\]             1998   Canada        7/9         serum         Radioimmunoassay                                  \-                                                Mixed                       SG       68                   NA                45/23
                                                                                                                                                                                                                                 CG       69                   NA                26/43
  Vezzoli \[[@B32-nutrients-09-00301]\]           1999   Italy         7/9         plasm         Radioreceptor assay                               \-                                                Calcium oxalate             HSG      37                   NA                NA
                                                                                                                                                                                                                                 NSG      27                   NA                NA
  Yamakawa \[[@B33-nutrients-09-00301]\]          2000   Japan         9/9         serum         Radioreceptor assay                               \-                                                Calcium                     SG       63                   55.7 ± 12.5       47/16
                                                                                                                                                                                                                                 CG       26                   55.9 ± 15.9       21/5
  Prie \[[@B34-nutrients-09-00301]\]              2001   France        7/9         serum         Radioimmunoassay                                  \-                                                Calcium                     HSG      207                  NA                NA
                                                                                                                                                                                                                                 NSG      28                   NA                NA
  Misael da Silva \[[@B35-nutrients-09-00301]\]   2002   Brazil        9/9         serum         Radioisotopic assay                               \-                                                NA                          SG       40                   34.77 ± 11.73     19/21
                                                                                                                                                                                                                                 CG       10                   32.4 ± 8.4        5/5
  Asplin \[[@B36-nutrients-09-00301]\]            2003   USA           7/9         serum         Radioreceptor assay                               \-                                                Calcium                     SG       22                   NA                15/7
                                                                                                                                                                                                                                 CG       37                   NA                14/23
  Ozkaya \[[@B37-nutrients-09-00301]\]            2003   Turkey        8/9         serum         Radioimmunoassay                                  \-                                                Calcium                     SG       64                   6.7 ± 3.5         26/38
                                                                                                                                                                                                                                 CG       90                   7.2 ± 2.3         47/43
  Moyano \[[@B38-nutrients-09-00301]\]            2007   Spain         9/9         serum         Radioimmunoassay                                  \-                                                NA                          SG       24                   45.5 ± 13.5       22/29
                                                                                                                                                                                                                                 CG       27                   48.6 ± 15.4       9/12
  Shakhssalim \[[@B39-nutrients-09-00301]\]       2011   Iran          9/9         serum         Enzyme Immunoassay                                \-                                                Calcium                     SG       106                  43.4 ± 6.9        106/0
                                                                                                                                                                                                                                 CG       109                  38.4 ± 6.9        109/0
  Fallahzadeh \[[@B40-nutrients-09-00301]\]       2012   Iran          9/9         serum         \-                                                Electrochemiluminescence                          NA                          SG       36                   0.7 ± 0.39        24/12
                                                                                                                                                                                                                                 CG       36                   0.7 ± 0.39        22/14
  Tang \[[@B41-nutrients-09-00301]\]              2012   USA           6/9         serum         \-                                                Radioimmunoassay                                  NA                          SG       757                  54 ± 22.29        453/304
                                                                                                                                                                                                                                 CG       15529                43 ± 23.68        7175/8354
  Yilmaz \[[@B42-nutrients-09-00301]\]            2013   Turkey        8/9         serum         Enzyme linked immunosorbent assay                 \-                                                NA                          SG       25                   8.08 ± 5.18       13/12
                                                                                                                                                                                                                                 CG       23                   10.2 ± 3.64       11/12
  Kim \[[@B43-nutrients-09-00301]\]               2014   Korea         9/9         serum         Radioimmunoassay                                  \-                                                Calcium                     SG       326                  45.8 ± 12.3       204/122
                                                                                                                                                                                                                                 CG       163                  NA                NA
  Nguyen \[[@B44-nutrients-09-00301]\]            2014   USA           7/9         serum         \-                                                Liquid chromatography and mass spectrometry       NA                          SG       13                   60 ± 10           8/5
                                                                                                                                                                                                                                 CG       1999                 53 ± 14           767/1232
  Ketha \[[@B45-nutrients-09-00301]\]             2015   USA           9/9         serum         Mass spectrometry                                 Mass spectrometry                                 Calcium                     SG       149                  NA                NA
                                                                                                                                                                                                                                 CG       201                  NA                NA
  Taylor \[[@B46-nutrients-09-00301]\]            2015   USA           9/9         plasma        Liquid chromatography--tandem mass spectrometry   Liquid chromatography--tandem mass spectrometry   Calcium                     SG       356                  57.4 ± 8.1        356/0
                                                                                                                                                                                                                                 CG       712                  57.4 ± 8.1        712/0
  Sierra \[[@B47-nutrients-09-00301]\]            2016   Spain         8/9         Serum         \-                                                NA                                                Calcium                     SG       239                  49.61 ± 13.64     NA
                                                                                                                                                                                                                                 CG       127                  52.09 ± 11.02     NA

NOS: Newcastle-Ottawa Scale; SD: standard difference; M/F: male/female; USA: United States of America; NA: not available; SG: stone group; CG: control group; HSG: hypercalciuria stone group; NSG: normocalciuria stone group.
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###### 

Sensitivity analysis of the meta-analysis.

  Items          Comparisons   Sample Size   Tests for Heterogeneity   Analysis Model   Test for Overall Effect   WWD pg/mL or ng/mL   Higher in                        
  -------------- ------------- ------------- ------------------------- ---------------- ------------------------- -------------------- ----------- -------------------- -----
  1,25(OH)~2~D   SG vs. CG     1601/1676     97%                       \<0.0001         Random                    2.22                 0.03        7.92 (0.93,14.91)    SG
                 CSG vs. CG    1352/1413     98%                       \<0.0001         Random                    2.26                 0.02        9.94 (1.34,18.56)    CSG
                 HSG vs. CG    305/630       95%                       \<0.0001         Random                    2.39                 0.02        13.21 (2.38,24.04)   HSG
                 NSG vs. CG    541/630       98%                       \<0.0001         Random                    1.55                 0.12        9.67 (−2.55,21.89)   NSG
                 HSG vs. NSG   420/609       65%                       0.002            Random                    1.88                 0.06        3.39 (−0.13,6.91)    HSG
  25(OH)D        SG vs. CG     997/1308      98%                       \<0.0001         Random                    1.48                 0.14        2.02 (−0.66,4.69)    SG
                 CSG vs. CG    801/1055      75%                       0.007            Random                    0.31                 0.75        0.33 (−1.76,2.43)    CSG
                 HSG vs. CG    105/232       0%                        0.78             Fixed                     3.09                 0.002       3.02 (1.10,4.93)     HSG
                 NSG vs. CG    112/232       85%                       0.01             Random                    0.07                 0.94        −0.21 (−5.70,5.29)   CG
                 HSG vs. NSG   190/172       77%                       0.005            Random                    2.53                 0.01        4.48 (1.01,7.95)     HSG

CI: confidence interval; WMD: weighted mean difference. SG: stone group; CG: control group; CSG: calcium stone group; HSG: hypercalciuria stone group; NSG: normocalciuria stone group.\* *p* \< 0.05 was considered statistically significant.
